Circio Holding ASA (OSL:CRNA)

Market Cap	44.58M
Revenue (ttm)	123.00K
Net Income (ttm)	9.50M
Shares Out	81.64M
EPS (ttm)	1.23
PE Ratio	0.45
Forward PE	2.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	403,740
Average Volume	831,213
Open	0.5200
Previous Close	0.5200
Day's Range	0.5200 - 0.5460
52-Week Range	0.5400 - 13.2000
Beta	1.50
RSI	41.33
Earnings Date	Apr 10, 2025

About Circio Holding ASA

Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles. The company was formerly known as Targovax ASA and changed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 9
• Stock Exchange: Oslo Børs
• Ticker Symbol: CRNA

Financial Performance

In 2023, Circio Holding ASA's revenue was 123,000, a decrease of -98.77% compared to the previous year's 10.00 million. Losses were -110.74 million, -74.42% less than in 2022.